COGT vs LGND
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
COGT · Cogent Biosciences$31.65 ▲ 6.98%
LGND · Ligand Pharmaceuticals$306.20 ▲ 2.41%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- COGT -2.5%
- LGND +46.3%
Head to head
| Metric | COGT | LGND |
|---|---|---|
| Price | $31.65 | $306.20 |
| Change today | ▲ 6.98% | ▲ 2.41% |
| Market cap | $5.49B | $6.12B |
| Return, 3 months | -23.8% | +3.6% |
| Return, year to date | -10.9% | +62.0% |
| Return, 1 year | +113.5% | +51.2% |
| P/E (TTM) | – | 123.0 |
| P/B | 12.2 | 6.4 |
| P/E percentile vs own 5y | 18th | 100th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -31.8% |
| Net profit growth (YoY) | -31.1% | -124.3% |
| Gross margin | – | 95.2% |
| Operating margin | – | 14.4% |
| Net margin | – | 20.3% |
| Return on equity | -146.5% | 5.4% |
| Analyst target vs. price | +73.4% | +19.4% |
| Analyst buy share | 89% | 100% |
| RSI (14) | 52 | 50 |
| 30-day volatility | 47.6% | 39.1% |
| Max drawdown, 1 year | -34.4% | -14.7% |
| Trend read | Leaning bullish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LGND is the largest of the group by market value.
- COGT has returned the most over the past year.
- LGND has been the calmest stock over the last 30 days.